Compare Ginkgo Bioworks Holdings Inc (DNA) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs JPMorgan Chase & Co — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.27 (market cap $505.73M), while JPMorgan Chase & Co trades at $365.22 (market cap $962.37B). The key difference: JPMorgan Chase & Co is far larger — about 1902.9× Ginkgo Bioworks Holdings Inc's market cap, and JPMorgan Chase & Co pays a 1.66% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | JPM | |
|---|---|---|
Market Cap | $505.73M | $962.37B |
Sector | Health | Financials |
52-Week High | $16.14 | $365.18 |
52-Week Low | $5.48 | $282.84 |
Enterprise Value | $607.68M | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.
DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.
JPMorgan Chase & Co. (JPM) trades at $362.04, up 0.63% daily, with a bullish technical outlook and strong earnings beats in recent quarters. The stock shows robust fundamentals, including a P/E of 15.51 and ROE of 18.43%, supported by revenue growth to $181.85B in 2025. Recent news highlights CEO Jamie Dimon's economic warnings and positive analyst sentiment ahead of Q1 2026 earnings.
Outlook is positive with a consensus price target of $374.18, offering ~3.4% upside, but risks include geopolitical tensions, cybersecurity threats, and volatile cash flows. Investors should weigh strong profitability against macroeconomic headwinds for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
